Form 4: Zivo Bioscience CEO John Payne Reports Stock Option Transactions

John Payne, CEO of Zivo Bioscience, reports the cancellation and grant of stock options in a recent SEC Form 4 filing.

Summary

• John Payne, the President and CEO of Zivo Bioscience, filed a Form 4 with the SEC on June 6, 2024.
• The filing details changes in his beneficial ownership of the company's stock due to option cancellations and grants.
• Specifically, options for an aggregate of 65,738 shares were canceled, and a replacement option for 167,180 shares with an exercise price of $7.96 was granted.
• Additionally, 50,251 options were granted at an exercise price of $7.96.
• The share amount and exercise price have been adjusted to reflect a 1 for 6 reverse stock split in October 2023.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock option transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about executive compensation.

Positives

• The grant of new stock options to the CEO could be seen as an incentive to improve company performance.
• The new options granted to the CEO vested immediately.

Negatives

• The cancellation of existing options, even with a replacement grant, could be viewed negatively if it suggests a change in the company's compensation strategy or performance expectations.

Risks

• The value of the stock options is dependent on the future performance of Zivo Bioscience's stock price.
• Changes in market conditions or company performance could impact the value of these options.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of future value creation.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. The specific terms of the grants, such as the exercise price and vesting schedule, are often tailored to the company's specific circumstances and strategic goals.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
• The size and terms of the option grants are typically benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• The stock option grants could potentially impact shareholders by diluting ownership if the options are exercised.
• The grants also incentivize the CEO to increase shareholder value.

Key Dates

Keywords

Zivo Bioscience, John Payne, stock options, SEC Form 4, beneficial ownership, equity incentive plan